home
about us
science
pipeline
newsroom
contact
menu
The BIG Phase 2 study (Gastric Cancer is moving forward!
Jul 17, 2026
The BIG Phase 2 study (Gastric Cancer is moving forward!Explore
Our paper in Nature Communications
May 7, 2026
Our paper in Nature Communications
Explore
FDA IND Approval secured for EXL01
Dec 4, 2025
FDA IND Approval secured for EXL01
Explore
Exeliom Biosciences secures €2.85M extension to Series A funding, bringing total round to nearly €12M
Oct 21, 2025
Exeliom Biosciences secures €2.85M extension to Series A funding, bringing total round to nearly €12M
Explore
BIG receives ANSM approval to start Part 2
Sep 26, 2025
BIG receives ANSM approval to start Part 2
Explore
Several EXL01 studies hit recruitment milestones
Sep 11, 2025
Several EXL01 studies hit recruitment milestones
Explore
BIG and Mother receive DSMB approvals
Jul 24, 2025
BIG and Mother receive DSMB approvals
Explore
Part 2 of Livediff Launched
Jul 10, 2025
Part 2 of Livediff Launched
Explore
DSMB approval for EXLIBRIS
Jun 26, 2025
DSMB approval for EXLIBRIS
Explore
Successful pre-IND meeting
May 22, 2025
Successful pre-IND meeting
Explore
First patient for MAINTAIN POP
Apr 17, 2025
First patient for MAINTAIN POP
Explore
End of recruitment for BIG
Apr 10, 2025
End of recruitment for BIG
Explore
First patient for MOTHER
Mar 27, 2025
First patient for MOTHER
Explore
End of recruitment Livediff part 1
Mar 20, 2025
End of recruitment Livediff part 1
Explore
Our paper in Gastroenterology
Jan 21, 2025
Our paper in Gastroenterology
Explore
Positive results for MAINTAIN Phase 1
Jan 15, 2025
Positive results for MAINTAIN Phase 1
Explore
MAINTAIN POP submitted to ANSM
Oct 10, 2024
MAINTAIN POP submitted to ANSM
Explore
First patient for Ex-Libris
Jul 31, 2024
First patient for Ex-Libris
Explore
First patient for BIG
Jul 24, 2024
First patient for BIG
Explore
Exeliom Biosciences collaborates with REMIND in MAINTAIN POP study
Jun 25, 2024
Exeliom Biosciences collaborates with REMIND in MAINTAIN POP study
Explore
Jun 12, 2024
ANSM approval for EX-LIBRIS
Explore
Bpifrance funding
Jun 5, 2024
Bpifrance funding
Explore
1M€ investment
May 29, 2024
1M€ investment
Explore
Exeliom Biosciences announces three phase II clinical trials in immuno-oncology with lead candidate combined with immune checkpoint inhibitors
Apr 11, 2024
Exeliom Biosciences announces three phase II clinical trials in immuno-oncology with lead candidate combined with immune checkpoint inhibitors
Explore
Exeliom is awarded a $500k grant from the Crohn's and Colitis Foundation!
Mar 4, 2024
Exeliom is awarded a $500k grant from the Crohn's and Colitis Foundation!
Explore
Exeliom Biosciences and Hospices Civils de Lyon announce clinical collaboration in recurrent Clostridioides difficile infection
#HealthcareInnovation #ClinicalTrial #CDI #Partnership #ExeliomBiosciences #HospicesCivilsdeLyon #MedicalResearch #HealthcareInnovation #ExeliomBiosciences #Biotech #Start-up #Microbiome #Cdiff
Nov 6, 2023
Exeliom Biosciences and Hospices Civils de Lyon announce clinical collaboration in recurrent Clostridioides difficile infection
Explore
Exeliom Biosciences Announces that the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 1 Clinical Trial of EXL01 in Crohn’s Disease
#biotech #crohn'sdisease #clinicalstudy #milestones #immunotherapy #microbiome #livebiotherapeutics
Oct 19, 2023
Exeliom Biosciences Announces that the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 1 Clinical Trial of EXL01 in Crohn’s Disease
Explore
New review on Faecalibacterium published in FEMS Microbiology Reviews explores its potential for human health
#Faecalibacterium #GutHealth #HealthResearch #Microbiome #Biotherapeutics #Biotech
Sep 21, 2023
New review on Faecalibacterium published in FEMS Microbiology Reviews explores its potential for human health
Explore
Exeliom Biosciences Announces Series A Extension and Final Closing with Total of €24 Million ($26 Million) to Progress the Clinical Development of its Lead Candidate in Immuno-Oncology and Infectious Diseases.
#funding #SeriesA #Clinicaltrials
Jun 30, 2023
Exeliom Biosciences Announces Series A Extension and Final Closing with Total of €24 Million ($26 Million) to Progress the Clinical Development of its Lead Candidate in Immuno-Oncology and Infectious Diseases.
Explore
SATT Paris-Saclay and Exeliom Biosciences Sign License Option Agreement to Develop Breakthrough Recombinant Protein Targeting Tryptophan Metabolism
Apr 27, 2023
SATT Paris-Saclay and Exeliom Biosciences Sign License Option Agreement to Develop Breakthrough Recombinant Protein Targeting Tryptophan Metabolism
Explore
Exeliom Biosciences Announces First Patient Enrolled in Phase 1 Study for the Maintenance in Remission in Adult Patients With Mild to Moderate Crohn's Disease
Mar 21, 2023
Exeliom Biosciences Announces First Patient Enrolled in Phase 1 Study for the Maintenance in Remission in Adult Patients With Mild to Moderate Crohn's Disease
Explore
Exeliom Biosciences announces approval of Clinical Trial Application from the Belgian Agency for Single Strain Live Biotherapeutic EXL01 (Faecalibacterium prausnitzii) for the treatment of Crohn’s Disease
Clinical Trial Live Biotherapeutics Crohn's Disease Belgium
Feb 24, 2022
Exeliom Biosciences announces approval of Clinical Trial Application from the Belgian Agency for Single Strain Live Biotherapeutic EXL01 (Faecalibacterium prausnitzii) for the treatment of Crohn’s Disease
Explore
Exeliom Biosciences opens pilot manufacturing unit for Live Biotherapeutics (LBPs) thanks to European H2020 Accelerator Program
Manufacturing
May 7, 2021
Exeliom Biosciences opens pilot manufacturing unit for Live Biotherapeutics (LBPs) thanks to European H2020 Accelerator Program
Explore
Exeliom Biosciences has been awarded a 2.5M€ H2020 Accelerator Program Grant from the European Innovation Council
H2020 Accelerator Program Live Biotherapeutics Manufacturing
Aug 3, 2020
Exeliom Biosciences has been awarded a 2.5M€ H2020 Accelerator Program Grant from the European Innovation Council
Explore
Exeliom Biosciences is awarded 1.8M€ DeepTech grant from Bpifrance to advance its lead program
Deeptech Bpifrance Microbiome
Aug 12, 2019
Exeliom Biosciences is awarded 1.8M€ DeepTech grant from Bpifrance to advance its lead program
Explore
Nextbiotix becomes Exeliom Biosciences
Nextbiotix Exeliom Biosciences
Feb 15, 2019
Nextbiotix becomes Exeliom Biosciences
Explore
Exeliom Biosciences is awarded I-Lab2018 from Bpifrance
I-lab2018 Bpifrance
Jul 23, 2018
Exeliom Biosciences is awarded I-Lab2018 from Bpifrance
Explore
Exeliom Biosciences (formerly Nextbiotix) raises €7 million to tackle inflammatory bowel diseases
Series-A Biotech Exeliom Biosciences Nextbiotix
Jul 5, 2018
Exeliom Biosciences (formerly Nextbiotix) raises €7 million to tackle inflammatory bowel diseases
Explore
Exeliom Biosciences joins Wilco Incubator
Wilco
Sep 27, 2017
Exeliom Biosciences joins Wilco Incubator
Explore
Exeliom Biosciences joins Paris Biotech Santé Incubator
Paris Biotech Santé
Sep 25, 2017
Exeliom Biosciences joins Paris Biotech Santé Incubator
Explore

newsroom

upcoming events

Discover

contact

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.